Pacira BioSciences, Inc. (PCRX) News
Filter PCRX News Items
PCRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PCRX News Highlights
- PCRX's 30 day story count now stands at 2.
- Over the past 15 days, the trend for PCRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PCRX are DAVE and DEC.
Latest PCRX News From Around the Web
Below are the latest news stories about PACIRA BIOSCIENCES INC that investors may wish to consider to help them evaluate PCRX as an investment opportunity.
Pacira Appoints Frank D. Lee as Chief Executive Officer-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (th |
Hedge Funds are Betting on These 14 Sliding StocksIn this article, we will take a look at the hedge funds that are betting on these 14 sliding stocks. To see more such companies, go directly to Hedge Funds are Betting on These 5 Sliding Stocks. Stocks jumped on December 6 after the release of yet another welcome data point for the Federal Reserve, […] |
Pacira (PCRX) Gets FDA Nod for Exparel's Label ExpansionThe FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks. |
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor canal block and sciatic nerve block in the popliteal fossa will significantly extend reach within more than 3 million lower extremity procedures — TAMPA, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to non-opioid pain managemen |
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberTAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 14th at 11:00AM GMT (6:00AM ET).35th Annual Piper Sandler Healthcare Conference on Tuesday, November 28th at 2:00PM ET. Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira. |
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call TranscriptPacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Call Transcript November 2, 2023 Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.72 EPS, expectations were $0.84. Operator: Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only […] |
Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?It is hard to get excited after looking at Pacira BioSciences' (NASDAQ:PCRX) recent performance, when its stock has... |
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View UpdatedPacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales. |
Pacira BioSciences Inc (PCRX) Reports Q3 2023 Financial ResultsNet Income of $10.9 Million Despite Slight Decrease in Total Revenues |
Pacira BioSciences Reports Third Quarter 2023 Financial Results-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023. Third Quar |